RPH-035 not checked

R-Pharm · L04785

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
7 active
7 in total · 6 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“300 mg/10 mL (30 mg/mL) concentrate for solution for infusions in a single-dose vial For the 1st and 2nd infusions, 300 mg (10 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL. For the 3rd infusion, 600 mg (20 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL”In the company’s words, NCT07597668 on ClinicalTrials.gov
Tested for
Multiple Sclerosis
Main trialPhase 1
“The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in comparison with the drug product Ocrevus® (F. Hoffmann-La Roche Ltd., Switzerland) when used in patients with multiple sclerosis (MS)”In the company’s words, NCT07597668 on ClinicalTrials.gov
Other names
ocrelizumab · L04785
Copy of
Ocrevus (Genentech Inc)Tested side by side with the original in NCT07597668

Other drugs for Multiple Sclerosis

All 54 drugs for Multiple Sclerosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 2 Jun 2026 A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
Phase 3Authorised not given For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
Phase 3Authorised not given Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
Phase 3/4Authorised not given Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS): a randomized controlled trial
Phase 4Authorised not given The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
Phase 3Authorised not given STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years
Phase 3Authorised not given A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow RPH-035

Following is part of Solo: you see every change to RPH-035 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in